|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Retinopathy of Prematurity | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Retinal Diseases | |||||
| 3 | More general conditions related to this trial | ||||
| Eye Diseases | |||||
| Infant, Newborn, Diseases | |||||
| Infant, Premature, Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Bevacizumab | |||||
| Conventional Laser for ROP | |||||
| 5 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| The University of Texas Health Science Center, Houston | |||||